AIM
ATNM icon

Axiom Investment Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Axiom Investment Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5 Buy
+5
New +$6 ﹤0.01% 523
2022
Q4 		– Sell
-5
Closed – – 110
2022
Q3 		$0 Buy
+5
New +$31 ﹤0.01% 414

Other funds holding ATNM

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Compass Financial Management Tampa, Florida $829M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Axiom Investment Management's ATNM Position: Q2 2026 in Review

Axiom Investment Management opened a new position in Actinium Pharmaceuticals (ATNM) in Q2 2026: 5 shares worth $5. The stake represents ﹤0.01% of the portfolio and ranks #523 among its holdings. This is a return to the name: Axiom Investment Management previously reported a position in ATNM as recently as Q3 2022.

Axiom Investment Management first reported a position in ATNM in Q3 2022 and has held it in 2 quarters since. 47 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.

  • Axiom Investment Management held 5 shares of Actinium Pharmaceuticals worth $5 as of Q2 2026.
  • Actinium Pharmaceuticals was a new Axiom Investment Management position in Q2 2026.
  • Actinium Pharmaceuticals made up ﹤0.01% of Axiom Investment Management's portfolio in Q2 2026, its #523 holding.
  • Axiom Investment Management first reported a position in Actinium Pharmaceuticals in Q3 2022 and has held it in 2 quarters since.
  • 47 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.

Based on Axiom Investment Management's 13F filing for Q2 2026, filed 31 Jul 2026.